drugset / Trial / NCT06668103
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label phase 2 study to evaluate the safety, tolerability and preliminary anti-tumour activity of ABSK043 in combination with Firmonertinib in patients with Epidermal Growth Factor Receptor-mutated (EGFRm+) locally advanced or metastatic NSCLC.
Timeline
- Start
- 2024-11-25
- Primary completion
- 2027-12-30
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABSK043 | Small molecule | 400 mg | Oral |
| Subject | ABSK043 | Small molecule | 800 mg | Oral |
| Background | Firmonertinib | Small molecule | 80 mg | Oral |